Company Overview and News

 
Shining The Light On Medical Properties Trust

2018-09-22 seekingalpha
MPW has carved a unique niche in the largest and fastest-growing segment of the U.S. economy.
MPW OHI

 
Getting Paid 8% To Ride The 'Silver Tsunami'

2018-09-19 seekingalpha
Skilled nursing facilities are covered by Medicare for a short period of time, and nursing homes are not covered by Medicare.
SNR OHI SBRA

1
Is The Dividend Of Omega Healthcare Investors Safe?

2018-09-13 seekingalpha - 1
The company raised its dividend for 22 consecutive quarters, but it has frozen its dividend this year.
OHI

 
10 Dividend Growth Stocks For September 2018

2018-09-08 seekingalpha
Ranking so many stocks allows me to identify top-ranked stocks by sector, but also reveals some issues with my ranking system, which I'll address in a future article.
VALU CMCSA KRG OHI

1
OHI / Omega HealthCare Investors, Inc. FORM 8-K (Current Report)

2018-09-07 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
OHI

 
OHI / Omega HealthCare Investors, Inc. 424B5 (Prospectus)

2018-09-07 sec.gov
CALCULATION OF REGISTRATION FEE
OHI

 
OHI / Omega HealthCare Investors, Inc. S-3ASR

2018-08-31 sec.gov
As filed with the Securities and Exchange Commission on August 31, 2018
OHI

18
DivGro Pulse: August 2018

2018-08-29 seekingalpha
My pulse articles are strategy-focused articles that monitor the health of DivGro, my portfolio of dividend growth stocks.
HD CMCSA WBA MAIN VLO CVS CMI PFS MSCA.CL MSCA ITW MSFT OHI QCOM HASI

 
OHI / Omega HealthCare Investors, Inc. null

2018-08-28 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C8W(# @;V)J#3P\+TQI;F5A
OHI

 
OHI / Omega HealthCare Investors, Inc. null

2018-08-28 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0S(# @;V)J#3P\+TQI;F5A
OHI

 
LTC Properties: A Real Alternative To Omega Healthcare Investors

2018-08-23 seekingalpha
The management team at LTC has done a significant amount of work to position the business for the future.
LTC OHI

31
DGI For The DIY: Q2 2018 Portfolio Update

2018-08-22 seekingalpha
There is uncertainty in the market, but I remain confident that my dividend income will continue its steady march higher.
WFCNP SKT KMI AAPL KMR STAG CVB ABBV MO WFC THO ROST EOG TGT CLDT ABBV DLR SBUX OHI OXY KMRFZ

134
RetirementRx's Mid-Year Review

2018-08-22 seekingalpha - 1
I am a dividend growth investor. My focus is on generating a dividend income to facilitate a smooth transition into retirement. I actively manage a real-life dividend growth portfolio called RetirementRx. RetirementRx, a plan and portfolio, was started in 2013 with a target retirement income equal to my 2013 salary ($120K) adjusted for 2% inflation. To achieve this dividend income, I must grow my organic dividend income by 8% YoY and support a 4% yearly increase in the cash contribution to the portfolio.
RAD FDX OHI

8
99 Achievers Show 10+ Years Of Dividend Hikes With 2.5%-9.7% August Yields

2018-08-22 seekingalpha - 1
Dividend Achiever stocks are distinguished by 10 or more straight years of higher dividends. The 266 Achiever equities are balanced by sectors and capitalization. PFM is their tracking ETF.
IBM HEP TLP MDP SEP MCY TCP VGR APU MDPEB WPC OHI MO IVZ

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to OHI / Omega HealthCare Investors, Inc. on message board site Silicon Investor.

Repeal Cannabis Prohibition for San Jose Residents Project Repeal Cannabis Prohibition for San Jose Residents Project Repeal Cannabis Prohibition for San Jose Residents Project The BOHICA position: The BOHICA position: The BOHICA position:
CAUSEWAY ENERGY formerly Ohio Resourses-CUW.V CAUSEWAY ENERGY formerly Ohio Resourses-CUW.V CAUSEWAY ENERGY formerly Ohio Resourses-CUW.V AHWY -- AudioHighway.com AHWY -- AudioHighway.com AHWY -- AudioHighway.com
EBI, Cohig now NASDAQ EAST EBI, Cohig now NASDAQ EAST EBI, Cohig now NASDAQ EAST OHIO Resources OHO.V OHIO Resources OHO.V OHIO Resources OHO.V
AudioHighWay - IPO AudioHighWay - IPO AudioHighWay - IPO AudioHighway AudioHighway AudioHighway
Internet Gambling prohibited ??? Internet Gambling prohibited ??? Internet Gambling prohibited ??? Continental Holdings Inc.u0026#034;COHIu0026#034; acquires STARNET. Continental Holdings Inc.u0026#034;COHIu0026#034; acquires STARNET. Continental Holdings Inc.u0026#034;COHIu0026#034; acquires STARNET.
CUSIP: 681936100